RSO-021

About Therapeutic Solutions International

Therapeutic Solutions International is a publicly traded biotech holding company (TSOI) with a mission to develop novel immunotherapies and regenerative medicines. Its core achievement lies in establishing a diversified portfolio of early-stage assets, primarily focused on natural killer (NK) cells and mesenchymal stem cells (MSCs), targeting cancer, neurological trauma, and inflammatory conditions. The company's strategy revolves around a capital-efficient holding structure, in-licensing promising science, and advancing programs through subsidiary entities to attract partnership capital. However, its progress is characterized by early, pre-clinical, and Phase I assets, with limited late-stage clinical validation and no commercial revenue to date.

About RS Oncology

RS Oncology is a private, clinical-stage biotech pioneering a novel approach to cancer therapy by targeting the mitochondrial antioxidant protein PRX3. The company's lead asset, RSO-021, has completed a Phase 1 trial and is now in a Phase 2 trial for multiple aggressive cancers, including malignant pleural mesothelioma and metastatic breast, ovarian, and non-small cell lung cancers. With a lean team and a focused pipeline, RS Oncology aims to address significant unmet needs in rare and late-stage metastatic cancers. The company is pre-revenue and operates as a typical drug development biotech, advancing its programs through clinical trials.

Therapeutic Areas